Why big pharma's paying attention to drug delivery

There are a great many market reports being sold out there, but a new one on drug delivery by Insight Pharma that might be worth a look. Advanced Drug Delivery Technologies: Enabling Drug Reformulations and Administration Routes seems to touch on all the major trends and issues in drug delivery. The report notes, correctly, that big pharma companies are paying more attention to drug delivery companies by finding new uses for known active ingredients. It discusses drug-delivery applications of nanotech, nucleic acid delivery, the resurgence of transdermal delivery technology, the role of alternative delivery in drug lifecycle management. Abstract

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.